{"contentid": 487949, "importid": NaN, "name": "Modified COVID-19 vaccines for variants to be fast-tracked, say regulators", "introduction": "Authorized COVID-19 vaccines that\u00e2\u0080\u00afare modified in response to new variants will not\u00e2\u0080\u00afneed a brand new\u00e2\u0080\u00afapproval or \u00e2\u0080\u009clengthy\u00e2\u0080\u009d clinical studies, according to new guidance\u00e2\u0080\u00affrom\u00e2\u0080\u00afthe\u00e2\u0080\u00afACCESS\u00e2\u0080\u00afConsortium \u00e2\u0080\u0093 a coalition of regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland.\u00e2\u0080\u00af", "content": "<p>Authorized COVID-19 vaccines that\u00e2\u0080\u00afare modified in response to new variants will not\u00e2\u0080\u00afneed a brand new\u00e2\u0080\u00afapproval or &ldquo;lengthy&rdquo; clinical studies, according to <a href=\"https://www.gov.uk/government/publications/access-consortium-guidance-on-strain-changes-in-authorised-covid-19-vaccines\">new guidance\u00e2\u0080\u00affrom\u00e2\u0080\u00afthe\u00e2\u0080\u00afACCESS\u00e2\u0080\u00afConsortium</a> &ndash; a coalition of regulatory authorities from the UK, Australia, Canada, Singapore and Switzerland.\u00e2\u0080\u00af</p>\n<p>The\u00e2\u0080\u00afguidance,\u00e2\u0080\u00afdeveloped by the UK&rsquo;s Medicines and Healthcare products Regulatory Agency (MHRA) and its ACCESS partners, lays out\u00e2\u0080\u00afwhat information\u00e2\u0080\u00afthe medicines regulators\u00e2\u0080\u00afwould need to approve any modifications to authorized COVID-19 vaccines, should virus mutations make them less effective at preventing the disease.\u00e2\u0080\u00af\u00e2\u0080\u00af</p>\n<p>According to the guidance,\u00e2\u0080\u00afvaccine manufacturers would need to provide\u00e2\u0080\u00afrobust\u00e2\u0080\u00afevidence that the modified vaccine produces an immune response,\u00e2\u0080\u00afbut\u00e2\u0080\u00aftime-consuming\u00e2\u0080\u00afclinical\u00e2\u0080\u00afstudies\u00e2\u0080\u00afthat do not add to the regulatory\u00e2\u0080\u00afunderstanding of a\u00e2\u0080\u00afvaccine&rsquo;s\u00e2\u0080\u00afsafety, quality or effectiveness\u00e2\u0080\u00afwould not be needed.\u00e2\u0080\u00afThis is because\u00e2\u0080\u00afresearchers are now better able to measure protection\u00e2\u0080\u00afby looking at antibodies in the blood following vaccination, reducing the need to\u00e2\u0080\u00afwait\u00e2\u0080\u00afand\u00e2\u0080\u00afsee\u00e2\u0080\u00afwhether or not\u00e2\u0080\u00afpeople in a trial become infected with the\u00e2\u0080\u00afdisease.\u00e2\u0080\u00afThis would significantly reduce the length of time taken for the modified vaccine to be ready for use.</p>\n<p>Alongside data on the immune response, the vaccine manufacturer would also be expected to provide\u00e2\u0080\u00afevidence\u00e2\u0080\u00afshowing the modified vaccine is safe and is of the expected quality. In addition, data from the original robust clinical trials and the ongoing studies on real-world use in millions of people\u00e2\u0080\u00afcould\u00e2\u0080\u00afbe used to support any\u00e2\u0080\u00afdecision by the regulators.\u00e2\u0080\u00af\u00e2\u0080\u00af</p>\n<h2><strong>Based on\u00e2\u0080\u00afregulatory process used for\u00e2\u0080\u00afseasonal flu vaccines</strong></h2>\n<p>This approach\u00e2\u0080\u00afis based on the tried and tested\u00e2\u0080\u00afregulatory process used for\u00e2\u0080\u00afseasonal flu vaccines, for which annual modifications are needed to match the strains circulating\u00e2\u0080\u00afeach\u00e2\u0080\u00afyear.\u00e2\u0080\u00af\u00e2\u0080\u00af</p>\n<p>&ldquo;Our priority is to get\u00e2\u0080\u00afeffective\u00e2\u0080\u00afvaccines to the public\u00e2\u0080\u00afin as short a\u00e2\u0080\u00aftime\u00e2\u0080\u00afas\u00e2\u0080\u00afpossible, without\u00e2\u0080\u00afcompromising on safety.\u00e2\u0080\u00afShould any modifications to authorized COVID-19 vaccines be necessary, this regulatory approach should help to do just that, said MHRA chief scientific officer Dr Christian Schneider.</p>\n<p>&ldquo;The announcement today also demonstrates the strength of our international partnerships with other regulators and how\u00e2\u0080\u00afour global work can help ensure faster access to life-saving vaccines in the UK and around the world.\u00e2\u0080\u00af\u00e2\u0080\u00afThe public should be confident that no vaccine would be approved unless the expected high standards of safety, quality and effectiveness are met,&rdquo; he concluded.\u00e2\u0080\u00af</p>\n<p>Image:&nbsp;coronavirus_credit_deposit_photos</p>", "date": "2021-03-04 16:26:00", "meta_title": "Modified COVID-19 vaccines for variants to be fast-tracked, say regula", "meta_keywords": "COVID-19, Vaccines, Variants, Approval, ACCESS partners, MHRA, Regulation, Guidance", "meta_description": "Modified COVID-19 vaccines for variants to be fast-tracked, say regulators", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-04 16:25:17", "updated": "2021-03-04 16:34:12", "access": NaN, "url": "https://www.thepharmaletter.com/article/modified-covid-19-vaccines-for-variants-to-be-fast-tracked-say-regulators", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "coronavirus_credit_deposit_photos-_largre.jpg", "image2id": "coronavirus_credit_deposit_photos_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Clinical trials, Medicines and Healthcare products Regulatory Agency", "sector_tag": "Pharmaceutical", "therapy area_tag": "Infectious diseases, Vaccines", "topic_tag": "Coronavirus, Focus On, Regulation", "geography_tag": "Australia, Canada, Singapore, Switzerland, UK", "company_tag": "MHRA", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-04 16:26:00"}